Zurcher Kantonalbank Zurich Cantonalbank Trims Holdings in RxSight, Inc. (NASDAQ:RXST)

Zurcher Kantonalbank Zurich Cantonalbank decreased its position in shares of RxSight, Inc. (NASDAQ:RXST) by 19.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,176 shares of the company’s stock after selling 2,190 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in RxSight were worth $454,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. CWM LLC raised its position in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the period. Nisa Investment Advisors LLC increased its stake in RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares in the last quarter. Quest Partners LLC bought a new stake in RxSight during the second quarter valued at about $41,000. KBC Group NV lifted its position in shares of RxSight by 63.6% in the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock valued at $61,000 after acquiring an additional 479 shares in the last quarter. Finally, Amalgamated Bank lifted its position in shares of RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after acquiring an additional 207 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Insiders Place Their Bets

In other RxSight news, insider Ilya Goldshleger sold 3,105 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $46.08, for a total transaction of $143,078.40. Following the sale, the insider now directly owns 42,246 shares in the company, valued at $1,946,695.68. This represents a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jesse Anderson Corley acquired 11,111 shares of the stock in a transaction dated Tuesday, November 12th. The stock was bought at an average cost of $45.37 per share, with a total value of $504,106.07. Following the completion of the purchase, the director now directly owns 468,571 shares in the company, valued at approximately $21,259,066.27. The trade was a 2.43 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 65,807 shares of company stock valued at $3,202,275 in the last three months. Corporate insiders own 9.36% of the company’s stock.

Wall Street Analyst Weigh In

RXST has been the subject of several research analyst reports. Jefferies Financial Group started coverage on RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Finally, UBS Group initiated coverage on shares of RxSight in a research report on Friday. They set a “buy” rating and a $52.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $63.63.

RxSight Stock Performance

RXST stock opened at $43.15 on Friday. The firm has a fifty day moving average price of $48.01 and a 200 day moving average price of $51.67. RxSight, Inc. has a fifty-two week low of $33.09 and a fifty-two week high of $66.54. The firm has a market cap of $1.74 billion, a PE ratio of -51.99 and a beta of 1.11.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.